MNKD NASDAQ
MannKind Corporation
1W: +13.8%
1M: -5.9%
3M: -11.0%
YTD: -32.1%
1Y: -29.4%
3Y: -7.3%
5Y: -18.8%
$3.80
-0.15 (-3.80%)
Weekly Expected Move ±10.3%
$3
$3
$4
$4
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
13 relationships12
As Filer
counterparties named
1
As Counterparty
mentioned by others
6
Rel. Types
2021-05-25
Earliest Filing
2025-10-09
Latest Filing
partner: 3
customer: 3
target: 2
supplier: 2
acquirer: 1
investor: 1
Counterparties (Filed by MNKD)
12 relationshipsCompanies named in MNKD's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| scPharmaceuticals Inc. | — | target | Target company acquired via tender offer and merger. | 2025-10-09 | View |
| Seacoast Merger Sub, Inc. | — | acquirer | Wholly owned subsidiary of MannKind used to acquire scPharmaceuticals. | 2025-10-09 | View |
| Broadridge Corporate Issuer Solutions, LLC | — | partner | Rights Agent for the Contingent Value Rights Agreement. | 2025-10-09 | View |
| United Therapeutics Corporation | UTHR | partner | Collaboration partner exercising an option to expand product scope under a license agreement with MannKind. | 2025-08-27 | View |
| scPharmaceuticals Inc. | — | target | Target company in the proposed merger agreement. | 2025-08-25 | View |
| Sagard Healthcare Funding Partners Borrower 2 SPE, LP | — | investor | Purchased a 1% royalty on global net sales of Tyvaso DPI for $150 million plus potential milestones. | 2024-01-02 | View |
| United Therapeutics Corporation | UTHR | partner | Original licensee under the License Agreement dated September 3, 2018, as amended. | 2024-01-02 | View |
| Amphastar Pharmaceuticals, Inc. | AMPH | supplier | Amphastar Pharmaceuticals, Inc. is a supplier to MannKind Corporation under a Supply Agreement amended on December 22, 2 | 2023-12-27 | View |
| United Therapeutics Corporation | UTHR | customer | Amendment to commercial supply agreement extending term and modifying non-renewal notification periods. | 2021-10-18 | View |
| United Therapeutics Corporation | UTHR | customer | MannKind entered into a commercial supply agreement for MannKind to manufacture and supply Tyvaso DPI and BluHale inhala | 2021-08-16 | View |
| United Therapeutics Corporation | UTHR | customer | MannKind entered into a commercial supply agreement to manufacture and supply Tyvaso DPI and BluHale devices to United T | 2021-08-16 | View |
| Amphastar Pharmaceuticals, Inc. | AMPH | supplier | Sixth Amendment to Supply Agreement extending term to 2027 and restructuring purchase commitments. | 2021-05-25 | View |
Mentioned As Counterparty
1 mentionsOther companies that named MNKD in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-21 | Other Events; Exhibits | View | |
| 2026-08-05 | Earnings Release; Exhibits | View | |
| 2026-07-24 | Unregistered Equity Sales; Other Events; Exhibits | View | |
| 2026-06-02 | Other Events | View | |
| 2026-05-28 | Other Events | View | |
| 2026-05-22 | Shareholder Vote | View | |
| 2026-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-12-15 | Financial Statements and Exhibits | View | |
| 2025-11-10 | Other Events | View | |
| 2025-11-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-09 | Entry into Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Creati | Agreement Acquisition | View |
| 2025-08-27 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-08-25 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-19 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-15 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-06 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-12-18 | Unregistered Sales of Equity Securities; Other Events | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR